Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off
New York, Jan 20, 2026, 19:13 ET — After-hours Corvus Pharmaceuticals shares surged over threefold on Tuesday following fresh data release on its experimental eczema pill. The biotech also announced plans to raise $150 million through an underwritten stock offering. After-hours trading saw the stock surge roughly 167% to $21.41, with about 84 million shares changing hands. This move matters…